CAPTIVATE India - A Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals With Type 2 Diabetes Mellitus (T2DM) in India
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- NCT07121114
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This is a cross-sectional study assessing the prevalence of Cardiovascular Disease and describing cardio-renal risk factors among individuals with Type 2 Diabetes Mellitus in India based on medical records.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
- Male or female individuals with type 2 diabetes mellitus (T2DM), aged above or equal to 18 years.
- A confirmed diagnosis of T2DM before ethical clearance at every participating institution.
- Medical records available between 01 January 2024 to 30 September 2024 ought to have the data points required for the primary and secondary objectives. Medical records must have at least 6 months (greater than or equal to 180 days) of follow-up data from the date of diagnosis.
Exclusion Criteria
- Diagnosis of Type 1 diabetes, or maturity-onset diabetes of the young (MODY).
- Known congenital heart disease or malformation.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of individuals with established Cardio Vascular Disease (CVD) From start of data collection to end of data collection (approximately 3 months) Proportion
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇮🇳Bangalore, Karnataka, India
Novo Nordisk Investigational Site🇮🇳Bangalore, Karnataka, India